HC Wainwright Initiates Coverage On Upcoming Complement Franchise Company Apellis Pharmaceuticals
HC Wainwright has initiated coverage on Apellis Pharmaceuticals Inc (NASDAQ:APLS) with a Buy rating and a $75 price target. The analyst expects Apellis’s…
European Commission Signs COVID-19 Drug Procurement Deal With Gilead
Gilead Sciences Inc (NASDAQ:GILD) and the European Commission signed a joint procurement agreement for rapid and equitable access to the COVID-19…
Scynexis Touts Postive Data For Ibrexafungerp For Vaginal Infections
Scynexis Inc (NASDAQ:SCYX) announced the presentation of positive outcomes from the CANDLE 304s nested sub-study of ibrexafungerp in recurrent vulvovaginal candidiasis…
Inovio Lays Out Corporate Reorganization To Extend Cash Runway Into 2024
Inovio Pharmaceuticals Inc (NASDAQ:INO) has implemented a corporate reorganization designed to extend its cash runway and focus on key clinical programs.…
Impel Commences Mid-Stage Autism Spectrum Disorder Study
Impel Pharmaceuticals (NASDAQ: IMPL) has dosed the first patient in a Phase 2a proof-of-concept study of INP105, nasal olanzapine, a widely used atypical, second-generation antipsychotic.
FDA Lifts Clinical Hold On Viking Therapeutics’ Rare Metabolic Disorder Study
The FDA has lifted the clinical hold placed on Viking Therapeutics Inc’s (NASDAQ:VKTX) trial of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD). …
Capricor Therapeutics Announces First Patient Dosed In Pivotal Phase 3 Study Of CAP-1002 For Treatment Of Duchenne Muscular Dystrophy
Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select
The Daily Biotech Pulse: FDA Tentatively Approves Avadel’s Narcolepsy Drug, European Approval Broadens AstraZeneca’s Enhertu in Breast Cancer, Pharma Giants’ Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: